CD19 and myeloid sarcoma: In neuroimmunological diseases, such as MG, NMOSD, and MS, CD19‐, BCMA‐, and MuSK‐targeted CAR‐T cells have shown promise in depleting pathogenic B cells and restoring immune balance in refractory cases.